IONS
Ionis Pharmaceuticals Inc

6,598
Mkt Cap
$11.4B
Volume
1.61M
52W High
$74.42
52W Low
$23.95
PE Ratio
-38.61
IONS Fundamentals
Price
$71.50
Prev Close
$71.50
Open
$71.69
50D MA
$60.39
Beta
0.69
Avg. Volume
3.37M
EPS (Annual)
-$3.04
P/B
18.02
Rev/Employee
$659,623.95
Loading...
Loading...
News
all
press releases
Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the company was named as a top employer to work for by Science magazine in its annual Top Employer survey of the biopharmaceutical and...
Business Wire·13h ago
News Placeholder
More News
News Placeholder
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2d ago
News Placeholder
Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., Ionis chief executive officer, was awarded the 2025 Lifetime Achievement Award from the Oligonucleotide...
Business Wire·3d ago
News Placeholder
Ionis to hold third quarter 2025 financial results webcast
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, October 29th at 11:30 a.m. Eastern Time to discuss its third quarter 2025 financial results...
Business Wire·8d ago
News Placeholder
BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL
FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.
Zacks·30d ago
News Placeholder
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal
Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.
Zacks·1mo ago
News Placeholder
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease
Guggenheim on Tuesday hiked the price target on the stock to $92 from $90 while keeping a ‘Buy’ rating on the shares.
Stocktwits·1mo ago
News Placeholder
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.
Zacks·1mo ago
News Placeholder
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.
Zacks·2mo ago
News Placeholder
IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies
In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months.
Stocktwits·2mo ago

Latest IONS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.